Researchers also reported results from a separate trial of a gene therapy the company is developing for PKP2-related arrhythmogenic cardiomyopathy.

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported fourth-quarter and full-year 2025 financial results ...

Sanofi (NASDAQ:SNY) is one of the best undervalued stocks under $50 to invest in now. Sanofi (NASDAQ:SNY) announced on March ...

IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of ...

Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.

Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyFDA written ...

Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for treatment-refractory hematological disorders with an acceptable safety profile. In contrast, preliminary reports suggest ...

- Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment - CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE ...

UC San Diego has received a $7.4 million grant to support the development of a first-of-its-kind stem cell-based gene therapy for Friedreich’s ataxia. The California Institute for Regenerative ...

Scientists have uncovered a surprising genetic workaround that helps cells cope with Friedreich’s ataxia, a rare and devastating disorder. Credit: Shutterstock Scientists discovered that reducing a ...